FibroBiologics shares surge 10.68% premarket after receiving HREC approval for Phase 1/2 trial of CYWC628 for diabetic foot ulcers.

jueves, 5 de febrero de 2026, 5:14 am ET1 min de lectura
FBLG--
FibroBiologics surged 10.68% in premarket trading following the announcement that.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios